Document resource
Background and Importance Diabetic macular oedema (DME) represents the most common cause of vision loss in diabetic patients. It’s characterised by retinal thickening in the macular area as a result of microvascular changes. Faricimab is one of the latest therapeutic strategies, making it relevant to evaluate its effectiveness in real-world clinical practice.Aim and Objectives To evaluate the effectiveness and durability of intravitreal faricimab in patients with DME who received a loading phase of at least three injections, those who received a single dose or those that maintained the prior anti-vascular endothelial growth factor (anti-VEGF) interval.Material and Methods Retrospective observational study of patients with DME treated with faricimab between February 2024 and August 2025 at a tertiary hospital. Demographic variables (age and sex), therapeutic history (naïve or switch) and effectiveness-related clinical variables (best-corrected visual acuity (BCVA) in logMAR scale before and after faricimab treatment, optical coherence tomography (OCT) findings and weeks dosing intervals (Q)) were collected. Statistical analyses were performed using SPSSv.22.Results A total of 38 patients (50% women) and 49 eyes were included, with a median age of 72 years (range 39–84). All patients were switched. Thirty eyes received three or more faricimab injections as a loading phase, ten received a single dose and nine maintained the prior anti-VEGF interval after the switch. The mean pre-treatment BCVA (LogMAR) was 0.40 ± 0.33 and post-treatment BCVA (LogMAR) was 0.38 ± 0.32 with no significant improvement (−0.01 [95% CI: −0.06 to 0.03]), nor within any subgroup. OCT showed anatomical improvement in 74.4% of treated patients. The mean inyection interval was 6.5 ± 2.1 weeks. A total of 84.1% of patients maintained an interval ≤Q8, 6.8% ≥Q10 and 3 patients (6.8%) discontinued treatment due to good outcomes. Only one patient required switching back to the prior anti-VEGF due to worsening.Conclusion and Relevance Faricimab demonstrated stability in visual acuity and short-term anatomical improvement on optical coherence tomography in most patients with diabetic macular oedema. The treatment interval of ≤Q8 reflects adequate drug durability. However, studies with larger sample sizes and longer follow-up periods are needed, as well as further research on different treatment regimens to optimise its effectiveness in real-world clinical practice.Conflict of Interest No conflict of interest